Raymond James analyst David Novak maintained a Buy rating on Knight Therapeutics (KHTRF) today and set a price target of C$10.25. The company’s shares closed last Monday at $5.85.
According to TipRanks.com, Novak is a 4-star analyst with an average return of 18.9% and a 65.0% success rate. Novak covers the Healthcare sector, focusing on stocks such as Ziopharm Oncology, Leap Therapeutics, and Zymeworks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $7.82 average price target.
See today’s analyst top recommended stocks >>
Knight Therapeutics’ market cap is currently $820.7M and has a P/E ratio of 30.73. The company has a Price to Book ratio of 1.08.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite.
